SFC Fluidics Partners with Duracell for Diabetes Innovation
SFC Fluidics Partners with Duracell for Diabetes Innovation
SFC Fluidics, Inc. is excited to announce a collaboration with Duracell U.S. Operations, Inc. This partnership focuses on integrating efficient power solutions into SFC's innovative dual-hormone insulin and glucagon delivery pod, known as Gemini™. The primary objective of this joint effort is to create long-lasting power sources that can be utilized in advanced wearable drug delivery systems aimed at effectively managing diabetes.
The Gemini™ System and Its Relevance
The Gemini™ device represents a significant leap in diabetes management technology. It is a miniaturized dual-hormone pump designed to accurately deliver both insulin and glucagon, effectively acting as an artificial pancreas to maintain stable blood glucose levels. This unique patch pump is especially beneficial for children and adolescents, as it permits precise dosing even in smaller amounts, making management simpler for young patients. Central to the Gemini™ device is the ePump®, an advanced microfluidic pumping system that ensures accurate delivery while enhancing patient safety by minimizing the risk of accidental dosing.
Collaboration Goals and Impact
The alliance between SFC and Duracell aims to harness Duracell's expertise in power solutions tailored for demanding applications like the Gemini™ ePump®. SFC's CEO, Anthony Cruz, is optimistic about this collaboration, noting that their innovations could significantly reduce over- and under-dispenses of insulin by up to 95%. Cruz mentions the importance of progressing towards a viable marketing strategy for an artificial pancreas in the United States, emphasizing the positive potential for patients.
Duracell's Vision in Healthcare
Duracell is a recognized leader in the battery manufacturing sector, continuously seeking to leverage its technological innovations to improve medical devices. Gulhande Sanay, President of Duracell Future Innovations, underscores the rewarding nature of developing battery technologies that can enhance people's lives. He expresses enthusiasm for working alongside SFC in their mission to advance healthcare. Together, they aim to bring the Gemini™ pod to market, promising improved healthcare solutions.
About SFC Fluidics
SFC Fluidics, Inc. is committed to advancing healthcare through innovative microfluidic technologies designed to improve the quality of life for individuals living with diabetes. The company aims to establish itself as a global leader in drug delivery systems, particularly in diabetes management, where they can provide unique products that enhance affordability and lifestyle. SFC Fluidics is also part of the VIC Technology Venture Development™ portfolio and thanks the National Institutes of Health, particularly the National Institute of Diabetes and Digestive and Kidney Diseases, for their support in funding various aspects of the Gemini device's development.
About Duracell U.S. Operations, Inc.
Duracell U.S. Operations, Inc. stands as a global frontrunner in the primary battery market, focusing on reliability and quality for its consumers. Known around the world, Duracell products are the backbone of devices that connect people, safeguard families, and enhance everyday experiences. Their cutting-edge battery technology empowers individuals to live life without boundaries. Duracell operates under the ownership of Berkshire Hathaway Inc., a massive holding company with diverse business interests.
Frequently Asked Questions
What is the collaboration between SFC Fluidics and Duracell about?
The collaboration aims to integrate Duracell's power solutions into SFC Fluidics' Gemini dual-hormone delivery system, enhancing diabetes treatment.
What is the Gemini™ device?
The Gemini™ is a miniaturized patch pump that delivers both insulin and glucagon, aiming to stabilize blood glucose levels for patients.
How does the ePump® technology benefit patients?
The ePump® ensures accurate dosing with increased safety, significantly reducing the chances of accidental overdosing or underdosing.
Why is this collaboration important for diabetes management?
This partnership could facilitate the introduction of next-generation wearable devices that reliably manage diabetes with less interference in daily life.
What is the mission of SFC Fluidics?
SFC Fluidics aims to advance healthcare by developing leading-edge microfluidic technologies, particularly for diabetes management, enhancing quality of life.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
